Life Science Investing Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
Life Science Investing Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
Life Science Investing Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Life Science Investing Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy in Sanfilippo Syndrome Type B
Life Science Investing Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Life Science Investing Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B
Skyharbour Announces Additional Uranium Property Staking Increasing Total Portfolio to Over 662,000 Hectares in the Athabasca Basin, Saskatchewan
Homerun Resources Inc. Announces Full Mining Permit and Finalization of the Definitive Lease Agreement With CBPM
Brunswick Exploration Announces Inferred Mineral Resource of 52.2Mt at 1.08% Li2O at Mirage with Additional Exploration Target
